Increased 5α-Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation

Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients

(2010) Niramol Chanplakorn et al.   BREAST CANCER RESEARCH AND TREATMENT

Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment

(2010) Kiyoshi Takagi et al.   ENDOCRINE-RELATED CANCER

New Developments in Intracrinology of Human Breast Cancer

(2009) Hironobu Sasano et al.   Annals of the New York Academy of Sciences

Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer

(2009) Hiroko Yamashita et al.   CANCER SCIENCE

Androgen biosynthetic pathways in the human prostate

(2008) Van Luu-The et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer

(2008) Louis Wing-Cheong Chow et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Intracrinology of estrogens and androgens in breast carcinoma

(2007) Hironobu Sasano et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY